MK-677 cost, pricing landscape, and comparison to injectable HGH.
What MK-677 costs across different access pathways — current research compound pricing, estimated compounding pharmacy pricing if Category 1 reclassification occurs, and a detailed cost comparison with injectable growth hormone therapy.
Current MK-677 pricing landscape
MK-677 is currently available as a research compound from various suppliers, though quality and legitimacy vary significantly. It is not available as a prescription medication — compounding pharmacies cannot legally prepare it while it remains FDA Category 2.
If MK-677 is reclassified to Category 1, licensed compounding pharmacies could legally prepare it with a valid prescription. Pricing estimates are based on comparable oral compounded compounds and pre-restriction pricing data.
| Access pathway | Monthly cost | Notes |
|---|---|---|
| Research compound (current) | $40–$80/month | Unregulated quality; no prescription needed; buyer assumes all risk |
| Compounded Rx (if reclassified) | $80–$200/month (est.) | Licensed 503A pharmacy; physician supervision; quality-controlled |
| Injectable HGH (comparison) | $500–$3,000+/month | FDA-approved; limited indications; requires daily injections |
MK-677 vs HGH cost comparison
The cost differential between MK-677 and injectable HGH is dramatic — even at the highest compounding pharmacy estimates, MK-677 would cost 3–15x less than pharmaceutical HGH. This price gap is a primary driver of interest in ibutamoren as an alternative to injectable growth hormone therapy.
However, MK-677 and injectable HGH are not equivalent. HGH provides exogenous growth hormone at precise doses, while MK-677 stimulates endogenous production to the upper range of physiological levels. For patients with diagnosed GH deficiency requiring supraphysiological replacement, injectable HGH remains the standard of care.
Insurance and coverage
MK-677 is not FDA-approved for any indication, so insurance coverage is not available for ibutamoren in any form. If it becomes available as a compounded prescription, it would be cash-pay in virtually all cases. HSA/FSA eligibility would depend on the plan administrator and whether a prescribing physician provides documentation of medical necessity.